Disclaimer: Due to limited expertise, errors are inevitable, and some information may not be the most up-to-date. Feel free to point out in the comments. This article is only an introduction to medical and health-related drugs, not a recommendation of treatment plans (if involved); this article does not constitute any investment advice.
In July 2025, NEWISH announced the completion of a multi-million yuan financing round B1. This round of financing was jointly invested by well-known Chinese institutions Broadcom Capital, Xic Venture Capital, and Excellence Meijia.The funds will be mainly used to advance the clinical Phase I and Phase II studies of the core pipeline.Against the backdrop of a tightening financing environment in the biopharmaceutical primary market, the successful completion of NEWISH's current round of financing reflects the capital market's high recognition of the company's self-developed STARi nucleic acid drug development technology platform and its clinical transformation capabilities.NEWISH is a biopharmaceutical innovation company specializing in gene therapy and other fields, focusing on the research of "China-originated" nucleic acid drugs with fully independent intellectual property rights of the First-in-class type. The company relies on the jointly developed STARi (Super Targeted Activation of T-cell Immune Response) nucleic acid drug development platform to research and develop a new generation of therapeutic cancer vaccines.At present, the company mainly focuses on niche tracks with unmet clinical needs, such as precancerous cervical lesions and postoperative recurrence of liver cancer. Several new drugs have entered the clinical development stage, including the therapeutic DNA gene drug for liver cancer, NWRD06, which received IND approval in May 2023, and the therapeutic HPV DNA gene drug, NWRD08, which received IND approval in October 2023. Clinical trial results show that NWRD08 has demonstrated significant advantages in both safety and efficacy. Administered via injection into the deltoid muscle of the upper arm, this drug not only avoids the trauma and potential risks associated with traditional surgery but also reduces the degree of lesions in a relatively short period, promoting the clearance of E6E7 genes or the virus. It is believed that as subsequent clinical trials progress, these two therapeutic vaccine drugs will bring good news to a wide range of patients with precancerous cervical lesions and hepatocellular carcinoma.
